Phase I study of a novel oral Janus kinase 2 (JAK2) inhibitor (SB15180) for patients with relapsed or refractory Hodgkin’s or NHL also included 18F-FDG PET/CT to evaluate baseline disease status and treatment response [105]. The gene discussed is JAK2; the disease is non-Hodgkin lymphoma.